HERLEV, Denmark, Feb. 6, 2024 /PRNewswire/ -- Nordic Bioscience, a leading biomarker company, today announced that the company's extracellular matrix (ECM) biomarker, PRO-C3 (nordicPRO-C3™) will be available as a research use only (RUO) product in China at LabCorp. All testing outside China continues to be offered exclusively at Nordic Bioscience's laboratories in Herlev, Denmark. The availability of PRO-C3 as RUO in China will allow drug developers and scientists in China pre-IVD access to PRO-C3, which will be offered via LabCorp in Shanghai.

PRO-C3 (nordicPRO-C3™) biomarker for chronic diseases with a fibrotic component to become available in China in a licence agreement between Nordic Bioscience and Roche, at LabCorp, Shanghai

The PRO-C3 biomarker is relevant for drug development in particularly chronic diseases with a fibrotic component e.g., non-alcoholic steatohepatitis (NASH, also known as MASH), idiopathic pulmonary fibrosis (IPF) and multiple cancer types with solid tumors.

"This collaboration will allow faster and broader access to Nordic's precision medicine enabling biomarker PRO-C3. We are very happy to be able to help drug developers in their efforts to bring new drugs for debilitating and deadly chronic diseases to market faster, more cost-efficiently, and in the future, have the potential to improve patients' lives" said Morten A. Karsdal, Chief Executive Officer of Nordic Bioscience.

The PRO-C3 biomarker quantifies the formation of type lll collagen via measurements in blood samples. Moreover, the FDA has recently issued a Letter of Support for further investigations of the PRO-C3 biomarker as a proposed prognostic biomarker in clinical trials of patients with solid tumors. Tumor fibrosis is a common denominator in a proportion of patients across solid tumor types and is associated with a more aggressive tumor progression and poor overall survival.

The PRO-C3 biomarker assay is measured on the fully automated cobas® e platform from Roche. Until now it has only been possible to measure PRO-C3 in the Nordic Bioscience laboratory in Herlev, Denmark, but RUO availability in China facilitates broader market access.

The license agreement between Nordic Bioscience and Roche will put multiple Nordic Bioscience biomarkers on the fully automated cobas® e platform from Roche over the coming years. This enables better research and drug development in chronic disease in which the ECM and collagens are central components. That is the case for almost 50 chronic diseases that until now have limited treatment options and represent a major challenge for patients and society.

For more information please contact:
Nordic Bioscience A/S
Herlev Hovedgade 205-207
2730 Herlev, Denmark
preferably via email agd@nordicbio.com
Tel. +45 4452 5252
For product related inquires please use https://www.nordicbioscience.com/contact 

About Nordic Bioscience

Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. Nordic Bioscience is engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.

 

 

Source: Nordic Bioscience